144 related articles for article (PubMed ID: 37166136)
1. Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!
Villanueva C; Tripathi D
Liver Int; 2023 Jun; 43(6):1154-1156. PubMed ID: 37166136
[No Abstract] [Full Text] [Related]
2. An advance in the treatment of portal hypertension?
Wong F; Blendis L
Gastroenterology; 2000 Apr; 118(4):802-3. PubMed ID: 10734033
[No Abstract] [Full Text] [Related]
3. Gastrointestinal bleeding: Carvedilol-the best beta-blocker for primary prophylaxis?
Tsochatzis EA; Triantos CK; Burroughs AK
Nat Rev Gastroenterol Hepatol; 2009 Dec; 6(12):692-4. PubMed ID: 19946301
[No Abstract] [Full Text] [Related]
4. The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis.
Fierbinteanu-Braticevici C; Udeanu M; Dragomir P; Andronescu D
Rom J Intern Med; 2003; 41(3):247-54. PubMed ID: 15526508
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol: the β-blocker of choice for portal hypertension?
Bosch J
Gut; 2013 Nov; 62(11):1529-30. PubMed ID: 23355548
[No Abstract] [Full Text] [Related]
6. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
7. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis.
Forrest EH; Bouchier IA; Hayes PC
J Hepatol; 1996 Dec; 25(6):909-15. PubMed ID: 9007720
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Sinagra E; Perricone G; D'Amico M; Tinè F; D'Amico G
Aliment Pharmacol Ther; 2014 Mar; 39(6):557-68. PubMed ID: 24461301
[TBL] [Abstract][Full Text] [Related]
9. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Hobolth L; Bendtsen F; Hansen EF; Møller S
Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol or propranolol in portal hypertension? A randomized comparison.
Hobolth L; Møller S; Grønbæk H; Roelsgaard K; Bendtsen F; Feldager Hansen E
Scand J Gastroenterol; 2012 Apr; 47(4):467-74. PubMed ID: 22401315
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol for portal hypertension in patients with cirrhosis.
Bosch J
Hepatology; 2010 Jun; 51(6):2214-8. PubMed ID: 20513005
[No Abstract] [Full Text] [Related]
12. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
De BK; Das D; Sen S; Biswas PK; Mandal SK; Majumdar D; Maity AK
J Gastroenterol Hepatol; 2002 Feb; 17(2):183-9. PubMed ID: 11966949
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol--A new nonselective beta blocker.
Forrest E; Stanley A; Hayes P
Hepatology; 2000 Mar; 31(3):809-11. PubMed ID: 10722317
[No Abstract] [Full Text] [Related]
14. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
Bruha R; Vitek L; Petrtyl J; Lenicek M; Urbanek P; Zelenka J; Jachymova M; Svestka T; Kalab M; Dousa M; Marecek Z
Scand J Gastroenterol; 2006 Dec; 41(12):1454-63. PubMed ID: 17101577
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
Shah HA; Azam Z; Rauf J; Abid S; Hamid S; Jafri W; Khalid A; Ismail FW; Parkash O; Subhan A; Munir SM
J Hepatol; 2014 Apr; 60(4):757-64. PubMed ID: 24291366
[TBL] [Abstract][Full Text] [Related]
16. A Patient with Dilated Cardiomyopathy and Portal Hypertension: Which Beta-Blocker to Use?
Sarkar R; Paul R; Roy D; Saha A; Sau TJ; Mondal J
J Assoc Physicians India; 2017 Sep; 65(9):107. PubMed ID: 29313593
[No Abstract] [Full Text] [Related]
17. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
Sinha R; Lockman KA; Mallawaarachchi N; Robertson M; Plevris JN; Hayes PC
J Hepatol; 2017 Jul; 67(1):40-46. PubMed ID: 28213164
[TBL] [Abstract][Full Text] [Related]
18. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.
Tripathi D; Therapondos G; Lui HF; Stanley AJ; Hayes PC
Aliment Pharmacol Ther; 2002 Mar; 16(3):373-80. PubMed ID: 11876689
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
20. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
Sekiyama T; Komeichi H; Nagano T; Ohsuga M; Terada H; Katsuta Y; Satomura K; Aramaki T
Arzneimittelforschung; 1997 Apr; 47(4):353-5. PubMed ID: 9150854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
